Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III

Vaccine

Volumn 29, Issue 17, 2011, Pages 3213-3221

  Lancaster, Lorna ^a   Saydam, Manolya ^a   Markey, Kevin ^a   Ho, Mei Mei ^a   Mawas, Fatme ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Conjugate vaccine; Group B streptococcus; Immunogenicity; Physico chemical

Indexed keywords

IMMUNOGLOBULIN G; STREPTOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CIRCULAR DICHROISM; CONJUGATE; CONTROLLED STUDY; FEMALE; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS AGALACTIAE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TYPING TECHNIQUES; FEMALE; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PHAGOCYTOSIS; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE;

EID: 79954594691     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.039     Document Type: Article

References (50)

1. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998, 11(3):497-513.
2. Baker C.J. Group B streptococcal infections. Clin Perinatol 1997, 24(1):59-70.
3. Schwartz B., Schuchat A., Oxtoby M.J., Cochi S.L., Hightower A., Broome C.V. Invasive sgroup B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA 1991, 266(8):1112-1114.
4. Edwards M.S., Baker C.J. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005, 41(6):839-847.
5. Skoff T.H., Farley M.M., Petit S., Craig A.S., Schaffner W., Gershman K., et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009, 49(1):85-92.
6. Barcaite E., Bartusevicius A., Tameliene R., Kliucinskas M., Maleckiene L., Nadisauskiene R. Prevalence of maternal group B streptococcal colonisation in European countries. Acta Obstet Gynecol Scand 2008, 87(3):260-271.
7. Heath P.T., Balfour G., Weisner A.M., Efstratiou A., Lamagni T.L., Tighe H., et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004, 363(9405):292-294.
8. Neto M.T. Group B streptococcal disease in Portuguese infants younger than 90 days. Arch Dis Child Fetal Neonatal Ed 2008, 93(2):F90-F93.
9. Berardi A., Lugli L., Baronciani D., Creti R., Rossi K., Ciccia M., et al. Group B streptococcal infections in a northern region of Italy. Pediatrics 2007, 120(3):e487-e493.
10. Yagupsky P., Menegus M.A., Powell K.R. The changing spectrum of group B streptococcal disease in infants: an eleven-year experience in a tertiary care hospital. Pediatr Infect Dis J 1991, 10(11):801-808.
11. Fluegge K., Siedler A., Heinrich B., Schulte-Moenting J., Moennig M.J., Bartels D.B., et al. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 2006, 117(6):e1139-e1145.
12. Grimwood K., Darlow B.A., Gosling I.A., Green R., Lennon D.R., Martin D.R., et al. Early-onset neonatal group B streptococcal infections in New Zealand 1998-1999. J Paediatr Child Health 2002, 38(3):272-277.
13. Bergseng H., Rygg M., Bevanger L., Bergh K. Invasive group B streptococcus (GBS) disease in Norway 1996-2006. Eur J Clin Microbiol Infect Dis 2008, 27(12):1193-1199.
14. Kalliola S., Vuopio-Varkila J., Takala A.K., Eskola J. Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. Pediatr Infect Dis J 1999, 18(9):806-810.
15. Vergnano S., Embleton N.D., Collinson A., Menson E., Bedford Russell A.R., Heath P.T. Missed opportunities for preventing GBS infections. Arch Dis Child Fetal Neonatal Ed 2009.
16. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299(17):2056-2065.
17. Davies H.D., Raj S., Adair C., Robinson J., McGeer A. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr Infect Dis J 2001, 20(9):879-884.
18. Weisner A.M., Johnson A.P., Lamagni T.L., Arnold E., Warner M., Heath P.T., et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 2004, 38(9):1203-1208.
19. Persson E., Berg S., Trollfors B., Larsson P., Ek E., Backhaus E., et al. Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998-2001. Clin Microbiol Infect 2004, 10(9):791-796.
20. von Both U., John A., Fluegge K., Siedler A., Berner R. Molecular epidemiology of invasive neonatal Streptococcus agalactiae isolates in Germany. Pediatr Infect Dis J 2008, 27(10):903-906.
21. Lachenauer C.S., Kasper D.L., Shimada J., Ichiman Y., Ohtsuka H., Kaku M., et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis 1999, 179(4):1030-1033.
22. Trager J.D., Martin J.M., Barbadora K., Green M., Wald E.R. Probable community acquisition of group B streptococcus in an infant with late-onset disease: demonstration using field inversion gel electrophoresis. Arch Pediatr Adolesc Med 1996, 150(7):766-768.
23. Schrag S., Schuchat A. Prevention of neonatal sepsis. Clin Perinatol 2005, 32(3):601-615.
24. Heath P.T., Feldman R.G. Vaccination against group B streptococcus. Expert Rev Vaccines 2005, 4(2):207-218.
25. Schuchat A. Neonatal group B streptococcal disease: screening and prevention. N Engl J Med 2000, 343:209-210.
26. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003, 188(1):66-73.
27. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Carey V.J., Hickman M.E., et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000, 182(4):1129-1138.
28. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21(24):3468-3472.
29. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hick M.E., et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999, 179(1):142-150.
30. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996, 98(10):2308-2314.
31. Baker C.J., Rench M.A., Paoletti L.C., Edwards M.S. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007, 25(1):55-63.
32. Whitmore L., Wallace B.A. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 2008, 89(5):392-400.
33. Whitmore L., Wallace B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 2004, 32(Web Server issue):W668-W673.
34. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984, 12(10):4063-4069.
35. Paoletti L.C., Pinel J., Kennedy R.C., Kasper D.L. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J Infect Dis 2000, 181(2):653-658.
36. Paoletti L.C., Kasper D.L. Conjugate vaccines against group B streptococcus types IV and VII. J Infect Dis 2002, 186(1):123-126.
37. Shen X., Lagergard T., Yang Y., Lindblad M., Fredriksson M., Holmgren J. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 2000, 19(7-8):850-861.
38. Baker C.J., Rench M.A., Edwards M.S., Carpenter R.J., Hays B.M., Kasper D.L. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988, 319(18):1180-1185.
39. Margarit I., Rinaudo C.D., Galeotti C.L., Maione D., Ghezzo C., Buttazzoni E., et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009, 199(1):108-115.
40. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science 2005, 309(5731):148-150.
41. Xue G., Yu L., Li S., Shen X. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice. FEMS Immunol Med Microbiol 2010, 58(2):202-210.
42. Guttormsen H.K., Mascuch S.J., West J.C., Paoletti L.C. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B streptococcus. Hum Vaccin 2009, 5(7):461-466.
43. Guttormsen H.K., Liu Y., Paoletti L.C. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccin 2008, 4(5):370-374.
44. Ho M.M., Lemercinier X., Bolgiano B., Crane D., Corbel M.J. Solution stability studies of the subunit components of meningococcal C oligosaccharide-CRM197 conjugate vaccines. Biotechnol Appl Biochem 2001, 33(Pt 2):91-98.
45. 197 conjugate by optical spectroscopy. Eur J Biochem 1997, 246(2):320-327.
46. Lewis A.L., Hensler M.E., Varki A., Nizet V. The group B streptococcal sialic acid O-acetyltransferase is encoded by neuD, a conserved component of bacterial sialic acid biosynthetic gene clusters. J Biol Chem 2006, 281(16):11186-11192.
47. Jennings H.J., Katzenellenbogen E., Lugowski C., Kasper D.L. Structure of native polysaccharide antigens of type Ia and type Ib group B streptococcus. Biochemistry 1983, 22(5):1258-1264.
48. Schifferle R.E., Jennings H.J., Wessels M.R., Katzenellenbogen E., Roy R., Kasper D.L. Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol 1985, 135(6):4164-4170.
49. Brigtsen A.K., Kasper D.L., Baker C.J., Jennings H.J., Guttormsen H.K. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 2002, 185(9):1277-1284.
50. Pollabauer E.M., Petermann R., Ehrlich H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009, 27(11):1674-1679.